NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.
RDI Initiates Coverage on:
Guardant Health, Inc.
Guardant Health, Inc. shares closed up almost 70% yesterday and hit a high of $35.50 on the company's first day of trading in the market. The cancer detection and treatment company's first trade yesterday was at $27.75 at 10:48 a.m. ET for 1.7 million shares. This compares to the stock's IPO price of just $19, also above the expected price of $15 to $17. The California-based company sells liquid biopsy tests that “map” out genomic results for advanced cancer tumors. This can help find the right cancer treatment for individuals. Guardant CEO Helmy Eltoukhy told CNBC on Thursday that the company's liquid biopsy, Guardant360, is a "big game changer." He said on 'Power Lunch', "Traditionally, late-stage patients would need a tissue biopsy — physically accessing and cutting a piece of their tumor tissue — for the physician to be able to match them with the most effective therapies. We can do that with a simple blood test in about half or a third of the time."
Access RDI’s Guardant Health, Inc. Research Report at:
Vaxart, Inc. shares closed up nearly 78% on Thursday with about 17.8 million shares traded. Shares were popping already in pre-market trading after the biotech company announced results from a phase 2 trial of its oral flu vaccine and said it performed better than Sanofi's Fluzone. "These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%," said Chief Scientific Officer Sean Tucker. He continued, "Further analysis of the data also confirm that, while our vaccine also generated protective hemagglutinin inhibition (HAI) antibodies in serum like conventional injectable flu vaccines, it primarily protected through the mucosal mechanism, providing a robust 39% reduction in illness versus placebo overall. In contrast, Fluzone, the market-leading injectable quadrivalent influenza vaccine, only provided a 27% reduction in illness versus placebo, while protecting primarily through HAI antibodies.” CEO Wouter Latour remarked, "We believe this clearly differentiates our oral vaccines from conventional injectable vaccines, and strongly suggests that vaccines based on Vaxart's proprietary vector adjuvant system could be optimal to protect against mucosal pathogens, including some of the major public health threats such as flu, norovirus, RSV and many others."
Access RDI’s Vaxart, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.